作者: Guillermo Guhl , Ana González-De Arriba , Esteban Daudén
DOI: 10.1016/S0001-7310(06)73407-X
关键词:
摘要: Epidermal growth factor receptor (EGFR) inhibitors are a new group of drugs used in the treatment several malignancies. Three molecules approved at moment: gefitinib and erlotinib for non-small-cell lung cancer, cetuximab colorectal cancer. These originate cutaneous side effects with high frequency: acneiform rashes, paronychia generalized xerodermia. In this paper we review these common how to manage them.